In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis

Heart. 2019 Dec;105(24):1868-1875. doi: 10.1136/heartjnl-2019-315103. Epub 2019 Aug 17.

Abstract

Objectives: Intraplaque angiogenesis and inflammation are key promoters of atherosclerosis and are mediated by the alpha-V beta-3 (αvβ3) integrin pathway. We investigated the applicability of the αvβ3-integrin receptor-selective positron emission tomography (PET) radiotracer 18F-fluciclatide in assessing human aortic atherosclerosis.

Methods: Vascular 18F-fluciclatide binding was evaluated using ex vivo analysis of carotid endarterectomy samples with autoradiography and immunohistochemistry, and in vivo kinetic modelling following radiotracer administration. Forty-six subjects with a spectrum of atherosclerotic disease categorised as stable (n=27) or unstable (n=19; recent myocardial infarction) underwent PET and CT imaging of the thorax after administration of 229 (IQR 217-237) MBq 18F-fluciclatide. Thoracic aortic 18F-fluciclatide uptake was quantified on fused PET-CT images and corrected for blood-pool activity using the maximum tissue-to-background ratio (TBRmax). Aortic atherosclerotic burden was quantified by CT wall thickness, plaque volume and calcium scoring.

Results: 18F-Fluciclatide uptake co-localised with regions of increased αvβ3 integrin expression, and markers of inflammation and angiogenesis. 18F-Fluciclatide vascular uptake was confirmed in vivo using kinetic modelling, and on static imaging correlated with measures of aortic atherosclerotic burden: wall thickness (r=0.57, p=0.001), total plaque volume (r=0.56, p=0.001) and aortic CT calcium score (r=0.37, p=0.01). Patients with recent myocardial infarction had greater aortic 18F-fluciclatide uptake than those with stable disease (TBRmax 1.29 vs 1.21, p=0.02).

Conclusions: In vivo expression of αvβ3 integrin in human aortic atheroma is associated with plaque burden and is increased in patients with recent myocardial infarction. Quantification of αvβ3 integrin expression with 18F-fluciclatide PET has potential to assess plaque vulnerability and disease activity in atherosclerosis.

Keywords: atherosclerosis; computed tomography; integrin; positron emission tomography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aorta, Thoracic / diagnostic imaging
  • Aorta, Thoracic / metabolism
  • Aortic Diseases / diagnostic imaging*
  • Aortic Diseases / metabolism*
  • Atherosclerosis / diagnostic imaging*
  • Atherosclerosis / metabolism*
  • Carboxylic Acids / pharmacokinetics
  • Carotid Stenosis / diagnostic imaging
  • Carotid Stenosis / metabolism
  • Cyclobutanes / pharmacokinetics
  • Female
  • Humans
  • Image Interpretation, Computer-Assisted / methods
  • Integrin alphaVbeta3 / metabolism*
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / metabolism
  • Positron Emission Tomography Computed Tomography / methods
  • Radiopharmaceuticals / pharmacokinetics
  • Vascular Calcification / diagnostic imaging
  • Vascular Calcification / metabolism

Substances

  • Carboxylic Acids
  • Cyclobutanes
  • Integrin alphaVbeta3
  • Radiopharmaceuticals
  • fluciclovine F-18